Inovio Pharmaceuticals Inc vs Energy Fuels Inc Ordinary Shares (Canada) — how do they compare? Inovio Pharmaceuticals Inc trades at $0.98 (market cap $101.95M), while Energy Fuels Inc Ordinary Shares (Canada) trades at $8.19 (market cap $2.21B). The key difference: Energy Fuels Inc Ordinary Shares (Canada) is far larger — about 21.7× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Energy Fuels Inc Ordinary Shares (Canada) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Energy Fuels Inc Ordinary Shares (Canada) for 0 Days on average.
| INO | UUUU | |
|---|---|---|
Market Cap | $101.95M | $2.21B |
Volume | 2,985,847 | 15,605,017 |
Sector | Health | Energy |
52-Week High | $2.60 | $27.72 |
52-Week Low | $0.66 | $8.34 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $73.28M | $1.95B |
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $0.9982, down 9.67% in the last session, with a bearish technical signal and negative financial metrics including a net income margin of -130,000%. The company shows consistent quarterly earnings beats but faces significant cash burn, with operating cash flow negative at -$88.63M in 2025. Key near-term catalyst is the FDA decision on INO-3107 expected by October 30, 2026.
INO presents high-risk speculative opportunity with analyst consensus price target of $2.75 representing 175% upside potential. The investment case hinges on successful FDA approval and commercialization of INO-3107, but carries substantial risk from persistent losses, negative cash flow, and dependence on financing activities to sustain operations.
Energy Fuels (UUUU) trades at $9.27, down 4.04% amid negative sentiment following a securities fraud investigation announcement. The stock shows weak technical positioning near recent lows with neutral indicators. Fundamentally, the company continues to report significant losses with a -77.3% net income margin despite revenue growth projections, while heavy investment in uranium and rare earth expansion creates substantial cash burn.
While analyst consensus remains bullish with a $21.06 price target representing 127% upside, execution risks are elevated. The securities investigation, persistent losses, and massive capital requirements for growth projects create substantial headwinds. Success depends on the company's ability to fund expansion and achieve profitability in the competitive critical minerals sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Energy Fuels Inc. is a US producer of uranium, vanadium, and rare earth elements. It operates the White Mesa Mill in Utah, the only fully licensed and operating conventional uranium processing facility in the country.
Read more on UUUU →